单纯治疗慢性前列腺炎对其合并早泄的影响

目的:探讨单纯治疗慢性前列腺炎对其合并早泄的影响。方法:选择372例前列腺炎继发早泄的患者进行单纯针对前列腺炎的治疗,评价前列腺炎的治疗效果(包括前列腺炎症状评分(NIH-CPSI)、前列腺液常规等)及早泄的治疗效果(包括患者性生活满意度评分、配偶性生活满意度评分及阴道内射精潜伏期等)。结果:慢性前列腺炎经综合治疗后,患者的NIH-CPSI评分及前列腺液白细胞计数均显著降低(P0.05)。前列腺炎治愈或好转后,大多数患者的早泄情况得到明显改善,患者性生活满意度、配偶性生活满意度均较治疗前显著提高,阴道内射精潜伏期亦较治疗前明显延长,差异均具有统计学意义(P0.05)。结论:单纯治疗慢性前列腺炎继可使大部分患者并发的早泄明显改善,而对少数前列腺炎好转后早泄症状改善不明显者,可联合应用SSRIs等药物治疗。     

电针配合中药熏蒸对慢性前列腺炎患者疗效和前列腺液中IL-17、TNF-α水平的影响

目的:探讨电针配合中药熏蒸对慢性前列腺炎患者疗效和前列腺液中白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)水平的影响。方法:选取2017年6月～2018年8月我院接收的慢性前列腺炎患者120例,根据随机数字表法分为观察组(n=60)和对照组(n=60)。对照组采用西医药物治疗,观察组采用电针配合中药熏蒸治疗。评价并比较两组疗效,比较两组患者治疗前后美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分、最大尿流率(Qmax)、平均尿流率(Qave)以及前列腺液IL-17、TNF-α水平。结果:观察组总有效率为90.00%,明显高于对照组的71.67%(P0.05)。治疗后,两组NIH-CPSI评分中的排尿症状、疼痛或不适、生活质量评分以及总分均明显降低,且观察组NIH-CPSI各维度评分及总分均低于对照组(P0.05)。治疗后,两组Qmax、Qave明显上升,且观察组Qmax、Qave明显高于对照组(P0.05)。治疗后,两组前列腺液IL-17、TNF-α水平明显降低,且与对照组比较,观察组IL-17、TNF-α水平明显更低(P0.05)。结论:电针配合中药熏蒸治疗慢性前列腺炎疗效确切,其能明显改善患者病情和尿流率,降低患者前列腺液中IL-17、TNF-α水平。     

宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎患者的临床疗效及对血清TNF-α、IL-1β、M-CSF的影响

目的:探讨宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎患者的临床疗效及对血清肿瘤坏死因子(TNF)-α、白介素(IL)-1β、巨噬细胞集落刺激因子(M-CSF)水平的影响。方法:选择2014年8月至2016年8月我院接诊的110例慢性前列腺炎患者,通过随机数表法分为观察组(n=55)和对照组(n=55)。对照组采用盐酸莫西沙星治疗,观察组联合宁泌泰胶囊治疗,均连续治疗2周。比较两组治疗前后慢性前列腺炎症状评分(NIH-CPSI)、前列腺液白细胞计数、血清TNF-α、IL-1β、M-CSF水平的变化及临床疗效。结果:治疗后,观察组临床疗效总有效率明显高于对照组(P0.05);两组NIH-CPSI评分、白细胞计数、血清TNF-α、IL-1β、M-CSF均较治疗前显著降低(P0.05),观察组以上指标均明显低于对照组(P0.05)。结论:宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎的临床效果显著,可有效缓解临床症状,安全性高,其机制可能和降低血清TNF-α、IL-1β、M-CSF水平相关。     

地奥司明对前列腺增生伴前列腺炎患者HSP, CRP及PSA的影响

目的:探讨地奥斯明对前列腺增生伴前列腺炎患者血清热休克蛋白(HSP)、C反应蛋白(CRP)及血清PSA水平的影响。方法:选取已确诊为前列腺增生伴前列腺炎的患者39例,随机分为实验组及对照组。对照组19例,予普适泰片治疗;实验组20例,予地奥司明治疗。28天为一个治疗疗程。比较两组患者治疗前后热休克蛋白、C反应蛋白及血清PSA水平的变化。结果:实验组总有效率(95.0%)高于对照组(78.9%),差异具有统计学意义(P0.05);与对照组比较,实验组热休克蛋白、C反应蛋白及血清PSA水平较低(P0.05),慢性前列腺炎评分(NIH-CPSI)评分较低(P0.05),不良反应发生率(10.0%)低于对照组(31.6%),差异存在统计学意义(P0.05)。结论:地奥司明片可以明显改善男性前列腺增生伴前列腺炎患者的排尿困难及尿频尿急等症状,有效降低患者热休克蛋白、C反应蛋白及血清PSA水平。     

甲磺酸多沙唑嗪控释片联合中药坐浴治疗老年非细菌性前列腺炎的临床疗效

目的:探讨甲磺酸多沙唑嗪控释片联合中药坐浴治疗老年非细菌性前列腺炎的临床疗效。方法:选取我院泌尿男科收治的老年非细菌性前列腺炎患者60例,随机分配为实验组和对照组,每组各30例,对照组患者使用甲磺酸多沙唑嗪控释片进行治疗,实验组患者在对照组的治疗基础上加用中药坐浴进行治疗,两组患者均治疗1个月。治疗结束后对患者前列腺液中的WBC水平进行检测,并应用美国国家卫生研究院慢性前列腺炎症状指数(NIH-CPSI)表对患者的前列腺功能进行评分,同时比较治疗结束后两组患者临床总有效率。结果:与治疗前相比,两组患者WBC计数及NIH-CPSI评分均有所降低(P0.05);与对照组相比,实验组患者治疗后WBC计数及NIH-CPSI评分较低(P0.05);临床总有效率较高(P0.05)。结论:甲磺酸多沙唑嗪控释片联合中药坐浴能够提高老年非细菌性前列腺炎患者的前列腺功能,降低炎症反应,临床疗效更好。     

超声电导靶向导入头孢菌素治疗慢性前列腺炎80 例的临床分析

目的:观察超声电导前列腺治疗仪经直肠导入二代头孢菌素(头孢呋辛)联合口服α受体阻滞剂(坦索罗辛)治疗Ⅲ型慢性前列腺炎的临床疗效。方法:将160例Ⅲ型慢性前列腺炎患者随机分为口服坦索罗辛组(对照组)和经直肠导入注射用头孢呋辛钠联合口服坦索罗辛组(治疗组)。对照组每天服药一次,共治疗6周。治疗组每天治疗1次,10天为一个疗程,两个疗程之间间隔7~10天,共3个疗程。采用慢性前列腺炎症状指数(NIH-CPSI)作为评分体系,分别观察和比较两组患者治疗前后的NIH-CPSI总分、疼痛评分、排尿评分和生活质量评分。结果:治疗组和对照组的总有效率分别为90.00%和68.8%,治疗组显著高于对照组(P0.05)。治疗后,两组患者的NIH-CPSI总评分、疼痛积分、排尿积分及生活质量评分都较治疗前显著改善(P0.05),且治疗组的症状改善较对照组更加明显,其各项评分均显著低于对照组(P0.05)。结论:采用超声电导前列腺治疗仪经直肠导入二代头孢菌素(头孢呋辛)联合口服α受体阻滞剂(坦索罗辛)可更加有效地治疗前列腺炎,改善患者的临床症状,并提高患者的生活质量,且毒副作用小,值得临床推广。     

高龄Ⅲ型前列腺炎患者血清和前列腺液中神经生长因子、炎性因子的表达水平及临床意义

目的:探讨高龄Ⅲ型慢性前列腺炎(CP)患者血清和前列腺液(EPS)中神经生长因子(NGF)、炎性因子的表达水平及其临床意义。方法:收集2015年5月~2016年12月我院收治的150例高龄Ⅲ型CP患者(CP组),其中ⅢA型81例,ⅢB型69例,另选择150例健康体检者作为对照(对照组)。采用双抗体夹心酶联免疫吸附法(ABC-ELISA)检测其血清、EPS中NGF、IL-8和TNF-α的表达水平,分析NIH-CPSI、NGF、IL-8和TNF-α之间的相关性。结果:CP组血清、EPS中TNF-α、IL-8、NGF水平均明显高于对照组(P0.05);与IIIB型患者比较,IIIA型患者TNF-α、IL-8水平明显升高(P0.05);EPS中TNF-α、IL-8、NGF水平均明显高于血清(P0.05)。IIIB型患者的NIH-CPSI症状评分明显低于IIIA型(P0.05)。CP患者EPS中NGF和TNF-α、IL-8均呈显著正相关(P0.05);血清中NGF和TNF-α、IL-8亦呈显著正相关(P0.05)。III型CP患者血清、EPS中,TNF-α、IL-8、NGF与NIH-CPSI呈显著正相关(P0.05)。结论:高龄III型CP患者血清、EPS中TNF-α、IL-8、NGF表达水平明显升高,且与NIH-CPSI明显相关,联合检测有助于评估III型CP患者的病情严重程度。     

普适泰治疗慢性ⅢA型前列腺炎患者的疗效及对前列腺液IFN-γ、TGF-β_1的影响

目的:探讨普适泰治疗慢性ⅢA型前列腺炎患者的疗效及对前列腺液干扰素-γ(IFN-γ)、转化生长因子-β_1(TGF-β_1)的影响。方法:选择2018年1月至2019年6月我院接诊的120例慢性ⅢA型前列腺炎患者,通过随机数表法分为观察组和对照组,每组60例。在常规处理基础上,对照组给予左氧氟沙星、坦索罗辛缓释胶囊治疗,观察组在对照组基础上,联合普适泰片治疗,均连续治疗连续用药12周。比较两组临床疗效、美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、前列腺液白细胞计数(WBC)、卵磷脂小体(HP)、IFN-γ、TGF-β_1的变化及不良反应。结果:治疗后,观察组临床疗效总有效率为93.33%,明显高于对照组的78.33%,差异有统计学意义(P0.05);观察组NIH-CPSI评分中疼痛和不适、排尿症状、症状严重程度及总分均明显低于对照组[(5.05±0.69)vs(6.33±0.74)分,(1.56±0.43)vs(2.70±0.55)分,(6.31±1.50)vs(7.92±1.64)分,(12.92±2.44)vs(16.95±2.87)分],差异有统计学意义(P0.05);观察组前列腺液WBC、IFN-γ、TGF-β_1明显低于对照组[(8.52±1.70)vs(10.04±1.58)个/HP,(8.06±1.32)vs(9.72±1.61)ng/L,(27.34±3.06)vs(42.57±3.89)ng/L],HP明显比对照组高[(81.06±5.75)vs(70.22±6.31)%],差异有统计学意义(P0.05);两组治疗期间恶心呕吐、乏力、心悸的总发生率比较差异无统计学意义(P0.05)。结论:在常规治疗基础上,联合普适泰治疗治疗慢性ⅢA型前列腺炎患者疗效显著,可有效促进症状恢复,降低前列腺液IFN-γ、TGF-β_1的表达,且不增加不良反应,值得应用推广。     

白芍总苷联合特拉唑嗪治疗非细菌性前列腺炎临床观察

目的:探讨白芍总苷联合特拉唑嗪治疗慢性非细菌性前列腺炎的临床效果.方法:将138例慢性非细菌性前列腺炎患者平均分为观察组和对照组,分别给予特拉唑嗪(2mg,每晚1次)+白芍总苷(0.6g,每天3次)和特拉唑嗪(2mg,每晚1次)治疗,12周后观察临床总体疗效、慢性前列腺炎症状指数(NIH-CPSI)评分及前列腺液常规.结果:观察组和时照组的临床总有效率、NIH-CPSI评分及前列腺液WBC计数均有显著改善,但观察组的改善程度均优于对照组.结论:白芍总苷联合特拉唑嗪治疗慢性非细菌性前列腺炎较单用特拉唑嗪疗效明显,值得临床推广.     

普适泰治疗慢性IIIA型前列腺炎患者的疗效及对前列腺液IFN-γ、TGF-β1的影响

摘要 目的：探讨普适泰治疗慢性IIIA型前列腺炎患者的疗效及对前列腺液干扰素-γ（IFN-γ）、转化生长因子-β₁（TGF-β₁）的影响。方法：选择2018年1月至2019年6月我院接诊的120例慢性IIIA型前列腺炎患者,通过随机数表法分为观察组和对照组,每组60例。在常规处理基础上,对照组给予左氧氟沙星、坦索罗辛缓释胶囊治疗,观察组在对照组基础上,联合普适泰片治疗,均连续治疗连续用药12周。比较两组临床疗效、美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）、前列腺液白细胞计数（WBC）、卵磷脂小体（HP）、IFN-γ、TGF-β₁的变化及不良反应。结果：治疗后,观察组临床疗效总有效率为93.33%,明显高于对照组的78.33%,差异有统计学意义（P＜0.05）;观察组NIH-CPSI评分中疼痛和不适、排尿症状、症状严重程度及总分均明显低于对照组[（5.05±0.69）vs（6.33±0.74）分,（1.56±0.43）vs（2.70±0.55）分,（6.31±1.50）vs（7.92±1.64）分,（12.92±2.44）vs（16.95±2.87）分],差异有统计学意义（P＜0.05）;观察组前列腺液WBC、IFN-γ、TGF-β₁明显低于对照组[（8.52±1.70）vs（10.04±1.58）个/HP,（8.06±1.32）vs（9.72±1.61）ng/L,（27.34±3.06）vs（42.57±3.89）ng/L],HP明显比对照组高[（81.06±5.75）vs（70.22±6.31）%],差异有统计学意义（P＜0.05）;两组治疗期间恶心呕吐、乏力、心悸的总发生率比较差异无统计学意义（P＞0.05）。结论：在常规治疗基础上,联合普适泰治疗治疗慢性IIIA型前列腺炎患者疗效显著,可有效促进症状恢复,降低前列腺液IFN-γ、TGF-β₁的表达,且不增加不良反应,值得应用推广。     

利奈唑胺对肾功能不全G~+感染患者血小板减少的相关性研究

目的:分析利奈唑胺对肾功能不全G+患者血小板减少的关系。方法:回顾性分析92例应用利奈唑胺治疗的革兰阳性球菌感染患者的临床资料,根据是否伴有肾功能不全分为肾功能不全组(33例),正常组(59例),检测用药前、用药后血小板计数,观察停药后血小板计数恢复正常时间及不良反应发生情况。结果:肾功能不全组治疗后血小板计数显著低于治疗前及正常组(P0.01),正常组治疗前、后血小板计数比较无统计学意义(P0.05);肾功能不全组血小板减少发生率高于正常组(P0.05);停药后正常组血小板恢复正常时间短于肾功能不全组(P0.01);肾功能不全组血红蛋白下降率高于正常组(P0.05),其余不良反应发生率比较差异无统计学意义(P0.05)。结论:感染患者肾功能可影响利奈唑胺所致血小板减少发生率,肾功能不全患者在应用利奈唑胺时应定期监测血小板计数。     

Effect of Pretreatment with Carbimazole in Patients with Thyrotoxicosis Subsequently Treated with Radioactive Iodine

Preliminary treatment with carbimazole in a series of 181 patients with thyrotoxicosis selected for treatment with radioactive iodine did not make any significant difference to the subsequent response to ¹³¹I therapy.     

Appearance of enterotoxigenic Escherichia coli in piglets with diarrhea in connection with feed changes

Twelve weaned piglet (3-week-old) were divided into three groups according to time of feed change and observed for diarrhea during the time they were 3 to 8 weeks of age. A total of 553 strains of Escherichia coli were isolated from rectal fecal samples and examined for heat-labile (LT) and heat-stable (ST) enterotoxins, pilus antigens (K88, K99, and 987P), hemolysin (Hly), raffinose utilization (Raf) and drug resistance. Enterotoxins and/or hemolytic E. coli strains appeared in the rectal feces of 5- to 6-week-old piglets with diarrhea in connection with feed change and changing temperatures. Most of the isolates showed multiple drug resistance to sulfonamides (Sa), streptomycin (Sp), ampicillin, and/or mercury. Enterotoxigenic E. coli isolates represented four phenotypes: K88+.LT+.Hly+.Raf+.(SaSmCpTcKmSp) (12 strains), K99+.ST+.Raf+.(TcKm) (7 strains), ST+.Raf+.(TcKm) (7 strains), and ST.+(SaSmKm) (25 strains). The drug resistance determinants were transferable concurrently and some of them mobilized the determinants for K88, LT, Hly, and Raf to an E. coli C strain.     

Immunologic correction with immunoglobulin of toxemia with exicosis in infants with acute intestinal infections]

The clinical course of acute intestinal infections complicated by toxicosis and exicosis was studied in 150 infants undergoing multimodality therapy, including natural human immunoglobulin for intravenous injections. The use of the new complex in the treatment of intestinal toxicoses was accompanied by increasing host immunological reactivity within short periods and decreasing of the treatment duration by 5.0 +/- 1.3 days; there were no persisting and chronic forms of the diseases and fatal outcomes. It was concluded that the use of the immunoglobulin for intravenous injections in the multimodality therapy of intestinal toxicoses in infants made it possible to prevent death in complicated intestinal infections and at the same time to accelerate their recovery.     

Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors

Motor activity in healthy young humans displays intrinsic fluctuations that are scale-invariant over a wide range of time scales (from minutes to hours). Human postmortem and animal lesion studies showed that the intact function of the suprachiasmatic nucleus (SCN) is required to maintain such scale-invariant patterns. We therefore hypothesized that scale invariance is degraded in patients treated for suprasellar tumors that compress the SCN. To test the hypothesis, we investigated 68 patients with nonfunctioning pituitary macroadenoma and 22 patients with craniopharyngioma, as well as 72 age-matched healthy controls (age range 21.0–70.6 years). Spontaneous wrist locomotor activity was measured for 7 days with actigraphy, and detrended fluctuation analysis was applied to assess correlations over a range of time scales from minutes to 24 h. For all the subjects, complex scale-invariant correlations were only present for time scales smaller than 1.5 h, and became more random at time scales 1.5–10 h. Patients with suprasellar tumors showed a larger decrease in correlations at 1.5–10 h as compared to healthy controls. Within healthy subject, gender and age >33 year were associated with attenuated scale invariance. Conversely, activity patterns at time scales between 10 and 24 h were significantly more regular than all other time scales, and this was mostly associated with age.

In conclusion, scale invariance is degraded in healthy subjects at the ages of >33 year as characterized by attenuation of correlations at time scales 1.5–10 h. In addition, scale invariance was more degraded in patients with suprasellar tumors as compared to healthy subjects.